Latest Life Sciences News

Invion Limited has announced a fully underwritten entitlement offer of Loyalty Options to raise capital for advancing its cancer clinical trials. The offer, led by Blue Ocean Equities and supported by CEO Prof Thian Chew, invites eligible shareholders to participate in a non-renounceable rights issue.

Lendlease has completed the $235 million sale of its 70% stake in Capella Capital to Sojitz Corporation, advancing its broader $2.5 billion capital recycling strategy aimed at simplifying the group and focusing on core Australian operations.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.

Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

EZZ Life Science has inked a three-year distribution deal with ROFA Enterprises, marking a significant step into Southeast Asia’s booming health market. The agreement guarantees at least A$21 million in sales across Thailand, Vietnam, and Singapore.

Wellnex Life Limited has had its trading suspension lifted following its response to ASX queries related to a recent shareholder letter, reopening market access to its shares.